These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8684621)

  • 1. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.
    Vila M; Levy R; Herrero MT; Faucheux B; Obeso JA; Agid Y; Hirsch EC
    Neuroscience; 1996 Apr; 71(4):903-12. PubMed ID: 8684621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
    Vila M; Levy R; Herrero MT; Ruberg M; Faucheux B; Obeso JA; Agid Y; Hirsch EC
    J Neurosci; 1997 Jan; 17(2):765-73. PubMed ID: 8987798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes.
    Vila M; Herrero MT; Levy R; Faucheux B; Ruberg M; Guillen J; Luquin MR; Guridi J; Javoy-Agid F; Agid Y; Obeso JA; Hirsch EC
    Neurology; 1996 Mar; 46(3):802-9. PubMed ID: 8618687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA.
    Levy R; Herrero MT; Ruberg M; Villares J; Faucheux B; Guridi J; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA
    Eur J Neurosci; 1995 Jun; 7(6):1199-209. PubMed ID: 7582093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
    Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
    Jouve L; Salin P; Melon C; Kerkerian-Le Goff L
    J Neurosci; 2010 Jul; 30(29):9919-28. PubMed ID: 20660274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
    Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
    Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum.
    Herrero MT; Levy R; Ruberg M; Luquin MR; Villares J; Guillen J; Faucheux B; Javoy-Agid F; Guridi J; Agid Y; Obeso JA; Hirsch EC
    Neurology; 1996 Jul; 47(1):219-24. PubMed ID: 8710082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intralaminar thalamic nuclei lesion on glutamic acid decarboxylase (GAD65 and GAD67) and cytochrome oxidase subunit I mRNA expression in the basal ganglia of the rat.
    Bacci JJ; Kerkerian-Le Goff L; Salin P
    Eur J Neurosci; 2002 Jun; 15(12):1918-28. PubMed ID: 12099898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
    Feher M; Gaszner B; Tamas A; Gil-Martinez AL; Fernandez-Villalba E; Herrero MT; Reglodi D
    Neurotox Res; 2018 May; 33(4):702-715. PubMed ID: 29230633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion.
    Porter RH; Greene JG; Higgins DS; Greenamyre JT
    J Neurosci; 1994 Nov; 14(11 Pt 2):7192-9. PubMed ID: 7965108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.
    Rolland AS; Herrero MT; Garcia-Martinez V; Ruberg M; Hirsch EC; François C
    Brain; 2007 Jan; 130(Pt 1):265-75. PubMed ID: 17148469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation.
    Betarbet R; Porter RH; Greenamyre JT
    J Neurochem; 2000 Mar; 74(3):1166-74. PubMed ID: 10693949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of nigrostriatal denervation in basal ganglia.
    Hirsch EC; Périer C; Orieux G; François C; Féger J; Yelnik J; Vila M; Levy R; Tolosa ES; Marin C; Trinidad Herrero M; Obeso JA; Agid Y
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S78-85. PubMed ID: 11052224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease.
    Meissner W; Guigoni C; Cirilli L; Garret M; Bioulac BH; Gross CE; Bezard E; Benazzouz A
    Eur J Neurosci; 2007 Mar; 25(5):1492-500. PubMed ID: 17425575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral high frequency stimulation of the subthalamic nucleus normalizes COX activity in the substantia nigra of Parkinsonian rats.
    Vlamings R; Visser-Vandewalle V; Kozan R; Kaplan S; Steinbusch HW; Temel Y
    Brain Res; 2009 Sep; 1288():143-8. PubMed ID: 19596282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.